Pharmaceutical Medicine

, Volume 26, Issue 2, pp 77–84

Portfolio Decisions in Early Development

Don’t Throw Out the Baby with the Bathwater
Current Opinion

Abstract

Portfolio decisions in early development happen under much uncertainty. Particularly when a novel target or treatment method is being explored, early negative clinical results may lead to the discontinuation of compound development, or even of an entire branch of discovery research. Although we can find examples where ‘failed’ concepts have been picked up later and shown to work, there is no way to estimate how large the percentage of false negative discontinuations may be as this type of information is not routinely added to publicly accessible databases; any analysis therefore is limited to specific articles and personal experience. Factors that favour false negative trials are known, and some of them can be influenced. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well designed dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data. Apart from following a more intelligent way of performing trials, the inherent mechanisms of human decision making need to be understood. Many of those decisions are not purely rational. Therefore, the findings of Kahneman and Tversky are very much applicable to early termination decisions. Thus, there are not only ways to prevent false negative clinical trials, but also clues to the psychology/mental frameworks that lead to erroneous conclusions in development. Awareness of such thinking may reduce the inclination to abandon an entire area of research based on only a few experimental data. The development of diagnostic tests can be used as an analogue to the decisions to be made in early clinical research, as such decisions can be classified according to false positives or false negatives, and so on, depending on the quality of the available information. It is hoped that the analysis of these early portfolio decisions will be based on data from public domain databases such as http://www.clinicaltrials.gov in the future.

References

  1. 1.
    Evans R, Hinds S, Hammock D. Portfolio analysis and R&D decision making. Nature Reviews Drug Discovery 2009; 8 (3): 189–90PubMedCrossRefGoogle Scholar
  2. 2.
    Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 2010; 9 (3): 203–14PubMedGoogle Scholar
  3. 3.
    Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3 (8): 711–5PubMedCrossRefGoogle Scholar
  4. 4.
    Booth M, Bundy DA. Comparative prevalences of Ascaris lumbricoides, Trichuris trichiura and hookworm infections and the prospects for combined control. Parasitology 1992; 105 (Pt 1): 151–7CrossRefGoogle Scholar
  5. 5.
    Jones D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 2010; 9 (9): 668–9PubMedCrossRefGoogle Scholar
  6. 6.
    Arrowsmith J. Trial watch: phase II failures: 2008–2010 [abstract]. Nat Rev Drug Discov 2011; 10 (5): 328–9PubMedCrossRefGoogle Scholar
  7. 7.
    Arrowsmith J. Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov 2011; 10 (2): 87PubMedCrossRefGoogle Scholar
  8. 8.
    Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007; 6 (11): 881–90PubMedCrossRefGoogle Scholar
  9. 9.
    Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 2004; 3 (5): 417–29PubMedCrossRefGoogle Scholar
  10. 10.
    Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 649–59PubMedCrossRefGoogle Scholar
  11. 11.
    Kahneman D, Tversky A. Variants of uncertainty. Cognition 1982; 11 (2): 143–57PubMedCrossRefGoogle Scholar
  12. 12.
    Kohlhardt M, Fleckenstein A. Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Br J Clin Pract Suppl. 1980; 8: 3–8PubMedGoogle Scholar
  13. 13.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341 (21): 1565–71PubMedCrossRefGoogle Scholar
  14. 14.
    Folkman J. A novel anti-vascular therapy for cancer. Cancer Biol Ther 2004; 3 (3): 338–9PubMedCrossRefGoogle Scholar
  15. 15.
    A stronger role for science [editorial]. Nat Rev Drug Discov 2011; 10 (3): 159Google Scholar
  16. 16.
    Arthritis Advisory Committee. Briefing document on belilumab. Rockville (MA): Human Genome Sciences, 2010 Oct 10Google Scholar
  17. 17.
    Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst 2011; 103 (1): 16–20Google Scholar
  18. 18.
    Hurko O, Jones GK. Valuation of biomarkers. Nat Rev Drug Discov 2011; 10 (4): 253–4PubMedCrossRefGoogle Scholar
  19. 19.
    Pritchard JF, Jurima-Romet M, Reimer ML, et al. Making better drugs: decision gates in non-clinical drug development. Nat Rev Drug Discov 2003; 2 (7): 542–53PubMedCrossRefGoogle Scholar
  20. 20.
    Munos B. Can open-source R&D reinvigorate drug research? Nat Rev Drug Discov 2006; 5 (9): 723–9PubMedCrossRefGoogle Scholar
  21. 21.
    Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 2009; 8 (7): 541–6PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen AF. Developing drug prototypes: pharmacology replaces safety and tolerability? Nat Rev Drug Discov 2010; 9 (11): 856–65PubMedCrossRefGoogle Scholar
  23. 23.
  24. 24.
    Whitehead J. Stopping clinical trials by design. Nat Rev Drug Discov 2004; 3 (11): 973–7PubMedCrossRefGoogle Scholar
  25. 25.
    Jones D. Adaptive trials receive boost. Nat Rev Drug Discov 2010; 9 (5): 345–8PubMedCrossRefGoogle Scholar
  26. 26.
    Agid Y, Buzsaki G, Diamond DM, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007; 6 (3): 189–201PubMedCrossRefGoogle Scholar
  27. 27.
    van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005; 4 (12): 961–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  1. 1.Clinical ResearchGlaxoSmithKline GmbH & Co. KGMunichGermany

Personalised recommendations